ESTIMATED
05/14/2024
05/14/2024
Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 0 | -$0.07 | -$0.07 | -$0.07 |
Q2 2024 | 1 | -$0.07 | -$0.07 | -$0.07 |
Q3 2024 | 0 | -$0.06 | -$0.06 | -$0.06 |
Q4 2024 | 0 | -$0.07 | -$0.07 | -$0.07 |
Brainstorm Cell Therapeutics Inc. last posted its earnings results on Tuesday, May 14th, 2024. The company reported $-0.05 earnings per share for the quarter, topping analysts' consensus estimates of $-0.07 by $0.02. The company had revenue of -569,000 for the quarter and had revenue of 0 for the year. Brainstorm Cell Therapeutics Inc. has generated $0 earnings per share over the last year ($-0.4 diluted earnings per share) and currently has a price-to-earnings ratio of -1.43. Brainstorm Cell Therapeutics Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 12th, 2024 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue | 05/14/2024 | Q1 2024 | -$0.07 | -$0.05 | 0.02 | $-569,000 | $-569,000 | 04/01/2024 | Q4 2023 | -$0.15 | -$0.11 | 0.04 | $0 | $343,000 | 09/29/2023 | Q3 2023 | -$0.03 | $0 | 08/14/2023 | Q2 2023 | -$0.15 | -$0.13 | 0.02 | $154,000 | 05/15/2023 | Q1 2023 | -$0.16 | -$0.14 | 0.02 | $-497,000 | 03/30/2023 | Q4 2022 | -$0.18 | -$0.14 | 0.04 | $0 | 11/14/2022 | Q3 2022 | -$0.15 | -$0.19 | -0.04 | $474,000 | 08/15/2022 | Q2 2022 | -$0.15 | -$0.18 | -0.03 | $204,000 | 05/16/2022 | Q1 2022 | -$0.13 | -$0.14 | -0.01 | $340,000 | 03/28/2022 | Q4 2021 | -$0.20 | -$0.17 | 0.03 | $0 | 11/15/2021 | Q3 2021 | -$0.21 | -$0.15 | 0.06 | $0 | 08/05/2021 | Q2 2021 | -$0.20 | -$0.17 | 0.03 | $87,000 | 04/26/2021 | Q1 2021 | -$0.27 | -$0.19 | 0.08 | $501,000 | 02/04/2021 | Q4 2020 | -$0.48 | -$0.33 | 0.15 | $0 | 10/15/2020 | Q3 2020 | -$0.24 | -$0.14 | 0.1 | $0 | 08/05/2020 | Q2 2020 | -$0.24 | -$0.25 | -0.01 | $823,000 | 05/07/2020 | Q1 2020 | -$0.23 | -$0.29 | -0.06 | $0 | 02/18/2020 | Q4 2019 | -$0.21 | -$0.27 | -0.06 | $750,000 | $-366,000 | 11/14/2019 | Q3 2019 | -$0.16 | -$0.25 | -0.09 | $750,000 | $1.04 M | 08/13/2019 | Q2 2019 | -$0.11 | -$0.23 | -0.12 | $2.25 M | $0 |
---|
A. Brainstorm Cell Therapeutics Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 12th, 2024 based off last year's report dates.
A. In the previous quarter, Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) reported $-0.05 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.07 by $0.02.
A. The conference call for Brainstorm Cell Therapeutics Inc.'s latest earnings report can be listened to online.
A. The conference call transcript for Brainstorm Cell Therapeutics Inc.'s latest earnings report can be read online.
A. Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) has a recorded net income of $0. Brainstorm Cell Therapeutics Inc. has generated $-0.4 earnings per share over the last four quarters.
A. Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) has a price-to-earnings ratio of -1.43 and price/earnings-to-growth ratio is -0.04.